Literature DB >> 26361935

Visual function test for early detection of ethambutol induced ocular toxicity at the subclinical level.

Kyoung Lae Kim1, Sung Pyo Park1.   

Abstract

CONTEXT: Tuberculosis in developed countries is on the rise, and the main treatment ethambutol is known to induce ocular toxicity. However, to date, there are unknown tests or protocols for detecting subclinical ethambutol-induced ocular toxicity, which is important as early detection is related to symptom reversibility. We defined the ethambutol induced ocular toxicity as stastically siginificant change of visual function which was induced by ethambutol.
OBJECTIVE: We aimed to identify a visual function test for the early detection of subclinical ethambutol-induced ocular toxicity. Furthermore, we also investigated the continuity or reversibility of early subclinical changes that were observed during the visual function tests after stopping ethambutol treatment.
MATERIALS AND METHODS: The age range of 31 patients was from 13 to 72 years. The range of dosage was 15-19 mg/kg/day. The average period of dosage was 5 months. We performed a visual acuity test, visual field test, color vision test, contrast sensitivity test, fundus examination, retinal nerve fiver layer optical coherence tomography test (RNFL OCT) per month and pattern visual evoked potential test (pattern VEP) every 2 months before and during ethambutol treatment in 62 eyes of 31 patients. Among these patients, selected 21 patients were rexamined by these tests at the 3, 6 and 12 months after stopping ethambutol treatment. We compared the test results from the last follow-up during ethambutol treatment and after ethambutol stoppage with those obtained before ethambutol treatment (baseline).
RESULTS: RNFL OCT showed that average RNFL thickness increased 5 months after ethambutol treatment (p = 0.032), and pattern VEP showed that P100 latency was delayed in 2 and 4 months after ethambutol treatment (p = 0.001; p < 0.001, respectively). These early changes observed on RNFL OCT and pattern VEP progressed 6 months after ethambutol stoppage in 21 patients. Twelve months after ethambutol stoppage, these early changes returned to baseline levels. During the study, no changes in visual acuity, color vision, fundus, contrast sensitivity or visual field were observed.
CONCLUSIONS: Pattern VEP and RNFL OCT are suitable tests for the early detection of subclinical ethambutol-induced ocular toxicity. These tests should be performed until 12 months after ethambutol stoppage.

Entities:  

Keywords:  Ethambutol; optic neuropathy; visual function test

Mesh:

Substances:

Year:  2015        PMID: 26361935     DOI: 10.3109/15569527.2015.1079784

Source DB:  PubMed          Journal:  Cutan Ocul Toxicol        ISSN: 1556-9527            Impact factor:   1.820


  9 in total

1.  Bilateral choroiditis as the only sign of persistent Mycobacterium intracellulare infection following haematogenous spread in an immunocompromised patient.

Authors:  Alessandro Invernizzi; Davide Ricaboni; Marco Franzetti; Giovanni Staurenghi; Peter McCluskey; Fabio Franzetti
Journal:  Infection       Date:  2017-12-09       Impact factor: 3.553

Review 2.  The rare ethambutol-induced optic neuropathy: A case-report and literature review.

Authors:  Wei Song; Shancheng Si
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

3.  The use of optical coherence tomography for the detection of ocular toxicity by ethambutol.

Authors:  Brunella Maria Pavan Taffner; Felipe Berno Mattos; Mariana Cartaxo da Cunha; Fábio Petersen Saraiva
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

4.  Longitudinal evaluation of visual function and structure for detection of subclinical Ethambutol-induced optic neuropathy.

Authors:  Ki Won Jin; Joo Yeon Lee; Soolienah Rhiu; Dong Gyu Choi
Journal:  PLoS One       Date:  2019-04-17       Impact factor: 3.240

5.  Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy.

Authors:  Rohit Saxena; Digvijay Singh; Swati Phuljhele; V Kalaiselvan; Satya Karna; Rashmin Gandhi; Anupam Prakash; Rakesh Lodha; Anant Mohan; Vimla Menon; Rajeev Garg
Journal:  Indian J Ophthalmol       Date:  2021-12       Impact factor: 1.848

Review 6.  Panomics for Precision Medicine.

Authors:  Charanjit Sandhu; Alia Qureshi; Andrew Emili
Journal:  Trends Mol Med       Date:  2017-12-05       Impact factor: 15.272

7.  Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease.

Authors:  Hyung-Jun Kim; Jong Sik Lee; Nakwon Kwak; Jaeyoung Cho; Chang-Hoon Lee; Sung Koo Han; Jae-Joon Yim
Journal:  BMC Pulm Med       Date:  2019-11-11       Impact factor: 3.317

8.  Analysis of structural injury patterns in peripapillary retinal nerve fibre layer and retinal ganglion cell layer in ethambutol-induced optic neuropathy.

Authors:  Wen-Yan Sheng; Ling-Ya Su; Wei Ge; Shuang-Qing Wu; Li-Wei Zhu
Journal:  BMC Ophthalmol       Date:  2021-03-10       Impact factor: 2.209

Review 9.  Visual electrophysiology in the assessment of toxicity and deficiency states affecting the visual system.

Authors:  Emily K O'Neill; Richard Smith
Journal:  Eye (Lond)       Date:  2021-07-21       Impact factor: 3.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.